1269233-04-6

Basic information

• Product Name: N-(3-bromo-2-fluorophenyl)propane-1-sulfonamide
• Synonyms: N-(3-bromo-2-fluorophenyl)propane-1-sulfonamide
• CAS NO: 1269233-04-6
• Molecular Weight: 296.16
• Mol File: 1269233-04-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(3-bromo-2-fluorophenyl)propane-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromo-2-fluorophenyl)propane-1-sulfonamide(1269233-04-6)
• EPA Substance Registry System: N-(3-bromo-2-fluorophenyl)propane-1-sulfonamide(1269233-04-6)

Safety Data

• Hazardous Substances Data: 1269233-04-6(Hazardous Substances Data)

Upstream product

• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 10147-36-1 n-propanesulfonyl chloride 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 58534-94-4 2-fluoro-3-bromonitrobenzene 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.